Albumin-Based Drug Delivery for Glioblastoma Treatment: Mechanistic Rationale, Preclinical Evidence, and Clinical Translation
Cells · 29.06.2026 · 15 (13) · 1180
DOI: 10.3390/cells15131180 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cells, online erschienen am 29.06.2026. Verfasst von Myung Geun Song und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Seoul National University College of Medicine, Seoul 03080, Republic of Korea. Hauptthemen laut MEDLINE: Glioblastoma, Albumins, Drug Delivery Systems, Brain Neoplasms. Die Arbeit nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea, the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea.
Abstract (Originalsprache)
Glioblastoma remains the most aggressive primary brain malignancy, with poor survival despite maximal safe resection, radiotherapy, and temozolomide-based chemotherapy. A major obstacle to effective treatment is the spatially heterogeneous blood–brain barrier/blood–tumor barrier, which restricts drug penetration into infiltrative tumor regions and limits uniform intratumoral exposure. Albumin-based delivery is attractive in glioblastoma because it addresses several formulation-level barriers at once: poor aqueous solubility of hydrophobic payloads, short systemic exposure, and the need for a biocompatible carrier that can interact with albumin-handling pathways such as gp60/albondin, SPARC, FcRn, and caveolin-associated transport. This review examines albumin-based strategies explored for glioblastoma, with an emphasis on albumin-bound paclitaxel nanoparticles, engineered albumin nanoparticles, dual-payload systems, albumin-binding photosensitizers, macrophage-assisted delivery, and albumin-bound pathway-directed agents. Preclinical evidence suggests that these platforms can improve brain-tumor drug exposure, support rational combinations, and synergize with BBB/BTB-opening technologies. Early clinical studies combining low-intensity pulsed ultrasound with microbubbles and albumin-bound paclitaxel provide human proof of concept for regional pharmacokinetic enhancement in recurrent glioblastoma, although survival benefit remains unproven. The available evidence supports albumin-based delivery as a rational formulation strategy. Its clinical value in GBM will depend on three testable requirements: spatial pharmacokinetic confirmation, biomarker-guided patient selection, and reproducible BBB/BTB modulation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine, Seoul National University College of Medicine, Seoul 03080, Republic of Korea.
- Biomedical Research Institute, Seoul National University Hospital, Seoul 03080, Republic of Korea.
- Department of Biomedical Sciences, Seoul National University Graduate School, Seoul 03080, Republic of Korea.
- Cancer Research Institute, Seoul National University College of Medicine, Seoul 03080, Republic of Korea.
ORCID-Profile: Keon Wook Kang
Förderung
- the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea
- the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea
Zitieren
APA
Song, M. G., & Kang, K. W. (2026). Albumin-Based Drug Delivery for Glioblastoma Treatment: Mechanistic Rationale, Preclinical Evidence, and Clinical Translation. Cells, 15(13), 1180. https://doi.org/10.3390/cells15131180
Vancouver
Song MG, Kang KW. Albumin-Based Drug Delivery for Glioblastoma Treatment: Mechanistic Rationale, Preclinical Evidence, and Clinical Translation. Cells. 2026;15(13):1180. doi:10.3390/cells15131180
BibTeX
@article{Song2026,
author = {Song, Myung Geun and Kang, Keon Wook},
title = {Albumin-Based Drug Delivery for Glioblastoma Treatment: Mechanistic Rationale, Preclinical Evidence, and Clinical Translation},
journal = {Cells},
year = {2026},
volume = {15},
number = {13},
pages = {1180},
doi = {10.3390/cells15131180}
}
EUVIMED